Literature DB >> 7634886

Pleural effusions in hospitalized patients receiving long-term hemodialysis.

M J Jarratt1, S A Sahn.   

Abstract

OBJECTIVE: To determine the incidence, causes, and clinical features of pleural effusions in hospitalized patients receiving long-term hemodialysis.
DESIGN: Retrospective. PARTICIPANTS: One hundred patients receiving hemodialysis for at least 3 months with pleural effusion hospitalized at the Medical University of South Carolina hospitals.
RESULTS: The incidence of pleural effusions in hospitalized patients receiving long-term hemodialysis was 21%. The mean (+/- SEM) age was 55 +/- 1.4 years and the male to female and black to white ratios were 3:2. Pleural effusions resulted from heart failure in 46% and nonheart failure causes in 54%. Uremic pleurisy (n = 16), parapneumonic effusion (n = 15), and atelectasis (n = 11) accounted for most of the nonheart failure causes of pleural effusions. Three of 15 (20%) parapneumonic effusions were empyemas. The presence of chest pain was not different in patients with parapneumonic effusions than in other patients with nonheart failure effusion (all p = NS) but was more frequent compared to those with heart failure (p = 0.006). Patients with parapneumonic effusions (p = 0.0006) and atelectasis (p = 0.003) were more likely to have unilateral pleural effusions than patients with heart failure.
CONCLUSIONS: Pleural effusions are common in hospitalized patients receiving chronic hemodialysis. Although heart failure was the most common cause, other diseases were responsible for most of the effusions. The presence of a unilateral effusion suggests a diagnosis other than heart failure, most commonly parapneumonic effusion or atelectasis and deserves prompt thoracentesis as these effusions often cannot be reliably differentiated clinically. The reduced humoral and cellular immunity, in addition to delay in diagnosis because of an attenuated clinical response, may explain the high rate of empyemas in this study population.

Entities:  

Mesh:

Year:  1995        PMID: 7634886     DOI: 10.1378/chest.108.2.470

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  8 in total

1.  Usefulness of a pleuroperitoneal shunt for treatment of refractory pleural effusion in a patient receiving maintenance hemodialysis.

Authors:  Masato Habuka; Toru Ito; Yuta Yoshizawa; Koji Matsuo; Shuichi Murakami; Daisuke Kondo; Hiroshi Kanazawa; Ichiei Narita
Journal:  CEN Case Rep       Date:  2018-03-23

2.  Video-assisted thoracoscopic surgery for thoracic empyema in patients on maintenance hemodialysis.

Authors:  Hsien-Chi Liao; Jen-Hao Chuang; Hsao-Hsun Hsu; Ke-Cheng Chen; Jin-Shing Chen
Journal:  Surg Endosc       Date:  2019-07-08       Impact factor: 4.584

3.  Effects of coexisting pneumonia and end-stage renal disease on pleural fluid analysis in patients with hydrostatic pleural effusion.

Authors:  Peter Doelken; John T Huggins; Mark Goldblatt; Paul Nietert; Steven A Sahn
Journal:  Chest       Date:  2013-06       Impact factor: 9.410

4.  Angiectasia of the parietal pleura in a hemodialysis patient with central venous stenosis and bloody pleural effusion: a case report.

Authors:  Yasuhiro Mochida; Takayasu Ohtake; Kunihiro Ishioka; Katsunori Miyake; Hidekazu Moriya; Sumi Hidaka; Shuzo Kobayashi
Journal:  CEN Case Rep       Date:  2020-09-02

5.  Refractory uraemic pleuropericarditis treated successfully with corticosteroid therapy.

Authors:  So-Young Lee; Gi-Youn Hong; Jun Gu Chung; Dong Ho Yang; Hyung-Jong Kim
Journal:  NDT Plus       Date:  2009-08-07

Review 6.  Presurgical pulmonary evaluation in renal transplant patients.

Authors:  Sonu Sahni; Ernesto Molmenti; Madhu C Bhaskaran; Nicole Ali; Amit Basu; Arunabh Talwar
Journal:  N Am J Med Sci       Date:  2014-12

7.  Pleural effusion in a patient with end-stage renal disease.

Authors:  Abeer Al-Harby; Othman Al-Furayh; Fouad Al-Dayel; Abdullah Al-Mobeireek
Journal:  Ann Saudi Med       Date:  2006 Mar-Apr       Impact factor: 1.526

Review 8.  Serous fluids and hematolymphoid disorders.

Authors:  Ali Gabali
Journal:  Cytojournal       Date:  2022-03-19       Impact factor: 2.345

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.